Académie royale de Médecine de Belgique


Résumé de Jean-Jacques Cassiman (Séance du 18 décembre 2010)



par J.-J. CASSIMAN (U.Z. – Leuven), invité.  

The possibilities for testing and screening for genes involved in inherited diseases or susceptibility to diseases have increased spectacularly. Combined with a revolution in the availability of sophisticated new technologies for testing, the question arises how we will be able to continue to provide quality services to our customers? Who will provide these? Will it be the centers, as we know them today, or will DTC take gradually over this service? Will the quality criteria, as established today before tests are made available, still be applicable and how will these new services be able to contribute to an increasing and coordinated collection of global information on genetic diversity and on the pathogenic changes in the human genome? As stated in the Bioethics Convention of the European Council and explicited in the recent recommendations from the House of Lords of the UK on Genomic Medicine, we will need a major effort of the European Commission, of our governments to implement a series of measures which will allow the correct and quality assured introduction into practice of the genetic knowledge that is being generated. Only then will all individuals and the scientific community be able to benefit from our services.